Related references
Note: Only part of the references are listed.Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice
Gaelle Naert et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro
Severine Coutadeur et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Hippocampal circuit dysfunction in the Tc1 mouse model of Down syndrome
Jonathan Witton et al.
NATURE NEUROSCIENCE (2015)
Dissecting Alzheimer disease in Down syndrome using mouse models
Xun Yu Choong et al.
Frontiers in Behavioral Neuroscience (2015)
Phosphorylation and Inactivation of Glycogen Synthase Kinase 3β (GSK3β) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A)
Woo-Joo Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Dosage of the Abcg1-U2af1 Region Modifies Locomotor and Cognitive Deficits Observed in the Tc1 Mouse Model of Down Syndrome
Damien Marechal et al.
PLOS ONE (2015)
PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition
Katja S. Kroker et al.
NEUROBIOLOGY OF AGING (2014)
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
Katheleen J. Gardiner
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl] (2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease
Johann Meunier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain
Md. Mahiuddin Ahmed et al.
HUMAN MOLECULAR GENETICS (2013)
Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 non-transgenic mouse model of Alzheimer's disease
Tangui Maurice et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer's disease rat model
Anthony Brureau et al.
NEUROBIOLOGY OF AGING (2013)
Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease
Valentine Lahmy et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-β Peptide Injection in Rats
Charleine Zussy et al.
PLOS ONE (2013)
Massively Parallel Sequencing Reveals the Complex Structure of an Irradiated Human Chromosome on a Mouse Background in the Tc1 Model of Down Syndrome
Susan M. Gribble et al.
PLOS ONE (2013)
Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y CELLS
Patchara Ngok-Ngam et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2013)
Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
Tania Tahtouh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Amyloid ß: linking synaptic plasticity failure to memory disruption in Alzheimer's disease
Tao Ma et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Altered regulation of tau phosphorylation in a mouse model of down syndrome aging
Olivia Sheppard et al.
NEUROBIOLOGY OF AGING (2012)
Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APPSwe/PS1 mice
Gaelle Naert et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2012)
Inhibition of Bax protects neuronal cells from oligomeric Aβ neurotoxicity
W. Kudo et al.
CELL DEATH & DISEASE (2012)
Time-Course and Regional Analyses of the Physiopathological Changes Induced after Cerebral Injection of an Amyloid β Fragment in Rats
Charleine Zussy et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol
Frank Edlich et al.
CELL (2011)
The role of DYRK1A in neurodegenerative diseases
Jerzy Wegiel et al.
FEBS JOURNAL (2011)
Overexpression of SOD in retina: Need for increase in H2O2-detoxifying enzyme in same cellular compartment
Shinichi Usui et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative
Vanessa Villard et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Modulation of GSK-3 as a therapeutic strategy on tau pathologies
Miguel Medina et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2011)
Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death
Hyoung Kyoung Choi et al.
Experimental Neurobiology (2011)
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: Evidence for A beta(25-35)
Yury G. Kaminsky et al.
EXPERIMENTAL NEUROLOGY (2010)
Imipramine, in Part through Tumor Necrosis Factor α Inhibition, Prevents Cognitive Decline and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease
F. Chavant et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid β25-35-Induced Toxicity in Mice
Vanessa Villard et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Mental retardation and associated neurological dysfunctions in Down syndrome: A consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways
Mohammed Rachidi et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2008)
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome
Fei Liu et al.
FASEB JOURNAL (2008)
Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801
A. Siddiqui et al.
GENES BRAIN AND BEHAVIOR (2008)
Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease
Soo-Ryoon Ryoo et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome
Elise Morice et al.
LEARNING & MEMORY (2008)
Arc/Arg3.1 translation is controlled by convergent N-methyl-D-aspartate and Gs-coupled receptor signaling pathways
Wendy A. C. Bloomer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Reduction in oxidative stress by superoxide dismutase overexpression attenuates acute brain injury after subarachnoid hemorrhage via activation of Akt/glycogen synthase kinase-3β survival signaling
Hidenori Endo et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35
B. Klementiev et al.
NEUROSCIENCE (2007)
Soluble protein oligomers in neurodegeneration:: lessons from the Alzheimer's amyloid β-peptide
Christian Haass et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease
Ryo Kimura et al.
HUMAN MOLECULAR GENETICS (2007)
The anti-amnesic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor
J. Meunier et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome
Ebrahim Abdul Shukkur et al.
HUMAN MOLECULAR GENETICS (2006)
The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation
Florian Plattner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome
Richard J. Siarey et al.
JOURNAL OF NEUROCHEMISTRY (2006)
RCAN1 (DSCR1 or Adapt78) stimulates expression of GSK-3β
G Ermak et al.
FEBS JOURNAL (2006)
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models
I Ferrer et al.
NEUROBIOLOGY OF DISEASE (2005)
An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes
A O'Doherty et al.
SCIENCE (2005)
Alzheimer disease and Down syndrome: factors in pathogenesis
IT Lott et al.
NEUROBIOLOGY OF AGING (2005)
A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons
G Morfini et al.
EMBO JOURNAL (2004)
Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain
JE Swatton et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice
N Noshita et al.
STROKE (2003)
Alzheimer's disease is a synaptic failure
DJ Selkoe
SCIENCE (2002)
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212:: potential role for DYRK as a glycogen synthase kinase 3-priming kinase
YL Woods et al.
BIOCHEMICAL JOURNAL (2001)
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
XJ Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3
A Giovanni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
